Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited announced the issuance of 100,000 ordinary shares following the exercise of vested employee performance rights. This move is part of the company’s efforts to enhance its operations and strengthen its position in the medical technology industry, particularly in the field of coronary artery disease management.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient diagnoses. Artrya is focused on advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 948,416
Technical Sentiment Signal: Buy
Current Market Cap: A$513.4M
For an in-depth examination of AYA stock, go to TipRanks’ Overview page.